# reload+after+2024-01-20 10:46:28.825048
address1§245 Hammersmith Road
city§London
zip§W6 8PW
country§United Kingdom
phone§44 20 3 808 8286
website§https://www.orchard-tx.com
industry§Biotechnology
sector§Healthcare
longBusinessSummary§Orchard Therapeutics plc, a gene therapy company, research, develops, and commercialize hematopoietic stem cell and gene therapies in the United Kingdom, Italy, France, and Germany. It offers OTL-200, an ex vivo autologous hematopoietic stem cell gene therapy for the treatment of patients with metachromatic leukodystrophy under the Libmeldy brand; and Strimvelis, a gammaretroviral vector-based gene therapy for the treatment of adenosine deaminase deficiency. The company's program for neurodegenerative disorders comprises clinical proof of concept-stage program, which includes OTL-203 for the treatment of mucopolysaccharidosis type I and OTL-201 for mucopolysaccharidosis type IIIA, or MPS-IIIA; and pre-clinical program, OTL-204 for the treatment of frontotemporal dementia with progranulin mutations. In addition, it develops program for immunological disorders consist of pre-clinical programs, which includes OTL-104 for Crohn's disease with mutations in the nucleotide-binding oligomerization domain-containing protein 2; and OTL-105 for the treatment of hereditary angioedema. The company was formerly known as Orchard Rx Limited. Orchard Therapeutics plc was founded in 2015 and is headquartered in London, the United Kingdom.
fullTimeEmployees§166
companyOfficers§[{'maxAge': 1, 'name': 'Dr. Hubert Baburaj Gaspar M.D., Ph.D.', 'age': 60, 'title': 'CEO, Member of Scientific Advisory Board & Executive Director', 'yearBorn': 1963, 'fiscalYear': 2022, 'totalPay': 901425, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Frank Edward Thomas', 'age': 54, 'title': 'President & COO', 'yearBorn': 1969, 'fiscalYear': 2022, 'totalPay': 763953, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Nicoletta  Loggia Ph.D., R.Ph.', 'title': 'Chief Technical Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Fulvio  Mavilio Ph.D.', 'title': 'Chief Scientific Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Ms. Renee T. Leck', 'title': 'Head of Investor Relations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Benjamin  Navon', 'title': 'Director of Corporate Communications', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. John  Cerio', 'title': 'Chief Human Resource Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Robin  Kenselaar', 'title': 'Senior VP & GM of EMEA Commercial Operations', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Mr. Braden  Parker', 'title': 'Chief Commercial Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}, {'maxAge': 1, 'name': 'Dr. Leslie  Meltzer Ph.D.', 'title': 'Chief Medical Officer', 'fiscalYear': 2022, 'exercisedValue': 0, 'unexercisedValue': 0}]
compensationAsOfEpochDate§1672444800
maxAge§86400
priceHint§2
payoutRatio§0.0
beta§0.553
priceToSalesTrailing12Months§17.092375
currency§USD
dateShortInterest§1702598400
forwardEps§-2.7
exchange§NCM
quoteType§EQUITY
shortName§Orchard Therapeutics plc
longName§Orchard Therapeutics plc
firstTradeDateEpochUtc§1540992600
timeZoneFullName§America/New_York
timeZoneShortName§EST
uuid§52e7dcb9-b744-3324-bdb7-d4182ec897c5
gmtOffSetMilliseconds§-18000000
targetHighPrice§16.0
targetLowPrice§16.0
targetMeanPrice§16.0
targetMedianPrice§16.0
recommendationMean§3.0
recommendationKey§hold
numberOfAnalystOpinions§1
quickRatio§2.884
grossMargins§-2.64105
ebitdaMargins§0.0
trailingPegRatio§None
